Warrant Programs

Promore Pharma issued in connection with the listing on Nasdaq First North 3,261,780 shares and 6,523,560 warrants. The warrants were listed on Nasdaq First North on 6 July 2017 with ticker PROMO TO1 and ISIN code SE0009997158.

Holders of warrants may subscribe for one share in Promore Pharma for every three warrants at a subscription price corresponding to 70 percent of a volume weighted average of the listing price for the Company share during the period 21 – 31 January 2019. The subscription price cannot be lower than 23.30 SEK per share or be higher than 46.60 SEK per share. The subscription period is 4 – 22 February 2019.

Find complete terms for the warrants here.

The Company has several warrant programs linked to the development of PXL01. Holders of these warrants are Technomark Group USA LLC, Kentron Biotechnology Pvt Ltd and PharmaReserch Products Ltd.

The exercise price for the warrants are SEK 13.30 per share, but will be adjusted to the quota value (SEK 0.04) if certain milestones are met in the development program. The warrants’ maturity is 31 December 2022.

No of warrants Holder No of shares fully exercised
2 273 Technomark 34 095
2 272 Kentron 34 080
2 300 Technomark 34 500
2 299 Kentron 34 485
9 078 Technomark 136 170
9 077 Kentron 136 155
9 078 Technomark 136 170
9 077 Kentron 136 155
4 573 Technomark 68 595
4 572 Kentron 68 580
9 078 Technomark 136 170
9 077 Kentron 136 155
4 573 Technomark 68 595
4 572 Kentron 68 580
45 455 PharmaResearch Products Ltd 681 825
    1 910 310